Kornimate/medical-research-clean huggingface dataset:
airway iga: respiratory tract iga levels in critically ill intubated patients

Conditions: Intubation; Critically Ill

Summary: this study will examine the impact of acute illness on sequential airway iga levels in intensive care patients who will require prolonged intubation. infections are the most common cause of late deaths in non-head injured trauma patients and a frequent cause of morbidity and mortality in hospitalized patients, especially intubated intensive care unit (icu) patients. nosocomial pneumonia is the most common of these infections, and its incidence in defined populations of critically injured patients is responsive to route and type of nutrition. this study will focus on the mechanisms of specific immune mucosal defenses in intestinal and extraintestinal sites and link enteral feeding (or lack of it) with maintenance (or deterioration) of respiratory mucosal defenses.


Eligibility criteria:
inclusion criteria: * subjects must be intubated, intensive care patients. exclusion criteria: * no severe pulmonary contusions or evidence of airway bleeding

Keywords: intubated patients
correct endotracheal tube placement using topographical landmarks

Conditions: Intubation, Intratracheal; Anatomic Landmarks

Summary: an optimal endotracheal tube depth is ideally required for preventing the complications associated with mal-positioning of the endotracheal tube. the topographical technique of tube placement considering the individual's morphometric dimensions could help to provide optimal tube placement. hence, to evaluate the efficacy of the topographical technique in providing the optimal tube placement this study will be conducted.

the trachea is a dynamic organ and its length varies by various static and dynamic factors leading to changing the tracheal length and variable endotracheal tube tip to carina (ti-ca) distance. hence, upholding optimal ti-ca distance during changing tracheal length is of utmost importance to prevent complications associated with endotracheal tube (ett) mal-positioning. when the length of ett, which is to be inserted inside the trachea, is calculated as per an individual's tracheal morphometric dimensions, the appropriate depth of placement could be achieved and tube malpositioning can be prevented. in the topographical landmark technique, an individual tracheal length is estimated by measuring the various distance from mid-thyroid level (corresponds to vocal cords) to manubriosternal joint (corresponds to carina) in the sagittal plane. after estimating the tracheal length, tip to carina distance of 3cm was deducted from the estimated length of the trachea to provide the distance of the endotracheal tube to be kept beyond the vocal cords. hence, the investigators planned this study to find the "utility and reliability" of the topographical landmark technique compared to the conventional intubation guide mark technique in providing the appropriate depth of endotracheal tube placement.

Eligibility criteria:
inclusion criteria: * • age group of 18-75 years * asa physical status i-iii patients * oral intubation for general anesthesia exclusion criteria: * • patient with upper airway fibrosis * tracheal stenosis or tracheal surgeries * previous head and neck surgeries * contracture neck or irradiated neck * large neck swelling distorting or deviating the trachea * laryngeal or tracheal tumor * intubations requiring flexo-metallic tubes * patient refusal

Keywords: endotracheal tube placement topographical landmarks of trachea
financial toxicity and quality of life in patients with tgct

Conditions: Testicular Neoplasm

Summary: this is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (tgct). as background, tgcts are the most common malignancies among men from age 15-35. treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. the treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. thus, we aim to study financial toxicity in both patients with tgct actively receiving treatment and in tgct survivors. there will be two separate cohorts: cohort 1 will consist of subjects with recently diagnosed tgct who will undergo multi-agent, multi-cycle chemotherapy and cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.


Eligibility criteria:
inclusion criteria: * age \> 18 years of age * patients with histologically or clinically confirmed germ cell tumor. * completed treatment for germ cell tumor with multicycle (\> 2 cycles) / multiagent chemotherapy. * within years 1-5 of surveillance since day 1 of last cycle of chemotherapy * signed informed consent exclusion criteria: * long-term survivors * patients undergoing active chemotherapy * patients who did not complete 1st line chemotherapy.
carpal tunnel release in diabetic patients

Conditions: Carpal Tunnel Syndrome; Diabetes; Nerve Entrapment

Summary: the aim of this study is to extend a previously reported 1 year follow-up on carpal tunnel release, in matched diabetic and non-diabetic patients,to compare outcomes 5 years after surgery.

the follow-up investigation includes: 1. clinical examination of sensory and motor function 2. generic and disease specific self-administered questionnaires 3. nerve conduction study 4. vibration threshold testing

Eligibility criteria:
inclusion criteria: * diabetic and non-diabetic patients operated for carpal tunnel syndrome 5 years ago. exclusion criteria: * previous carpal tunnel release in the hand under study * clinical signs of nerve entrapment other than cts * cervical radiculopathy, inflammatory joint disease * renal failure * thyroid disorders * previous wrist fracture on the affected side * daily long-term exposure to vibrating tools * pregnancy

Keywords: carpal tunnel syndrome entrapment neuropathies diabetes
validation of an eras protocol in gynecological surgery

Conditions: Surgery; Hysterectomy; Gynecologic Disease; Gynecologic Cancer; Anesthesia

Summary: validation of eras interventional measures in elective gynecological surgery, for benign either malignant pathology.


Eligibility criteria:
inclusion criteria: * age \>18 and \<75 years old * patients candidated for elective gynecological surgery for benign pathology * patients with diagnosis of gynecological neoplasm and candidated for elective gynecological surgery * signed consent form * karnofsky performance status \> 70 exclusion criteria: * asa score \> 3 * contraindication to loco-regional anaesthesia * patients with ileus or subocclusive condition prior surgery * coagulation disorders * organ failure or severe disfunction (heart, renal, pulmonary, hepatic) * uncontrolled hypertension (\>180/95) * alcohol or drug abuser (current or previous) * unability to self-care (pfs \< 70) * comorbidity-polypharmacy score \> 22 * psychiatric condition or language barriers * planned intensive care recovery

Keywords: eras, fast-track surgery, gynecology
systemic vegf protein dynamics following intravitreal injections of ranibizumab versus aflibercept in patients with visual impairment due to diabetic macular edema

Conditions: Visual Impairment Due to Diabetic Macular Edema

Summary: the purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic vegf protein levels in dme patients in a detailed time course.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus * visual impairment predominantly due to dme. exclusion criteria: * stroke or myocardial infarction less than 3 months prior to screening. * presence of uncontrolled systolic blood pressure or diastolic blood pressure * renal failure requiring dialysis or renal transplant or renal insufficiency * untreated diabetes mellitus * use of any systemic anti-vegf drugs * use of systemic or inhaled corticosteroids for at least 30 consecutive days within 3 months prior to screening. * women who are pregnant or breast feeding or who are menstruating and capable of becoming pregnant\* and not practicing a medically approved method of contraception for either eye: * any active periocular or ocular infection or inflammation * uncontrolled glaucoma * neovascularization of the iris or neovascular glaucoma * history of treatment with any anti-angiogenic drugs for study eye: * atrophy or fibrosis involving the center of the fovea at the time of screening or baseline. * cataract (if causing significant visual impairment), planned cataract surgery during the study period, vitrectomy, aphakia, glaucoma surgery, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization or macular edema of any other cause than dme * irreversible structural damage within 0.5 disc diameter of the center of the macula * panretinal laser photocoagulation within 6 months prior to randomization. * focal/grid laser photocoagulation within 3 months prior to randomization. * any intraocular procedure (including cataract surgery, yttrium-aluminum-garnet capsulotomy) within 3 months prior to baseline or anticipated within the next 6 months following * topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening. * application of intravitreal corticosteroids in vitreous within 6 months prior to screening. prior application of fluocinolonacetonid releasing implant in vitreous within 36 months prior to screening. for fellow eye - retinal or choroidal neovascularization or macula edema of any cause other protocol-defined inclusion/exclusion criteria may apply.
termination of early pregnancy in scarred uterus with lletrozole and misoprostol compared to misoprostol alone

Conditions: Termination of Early Pregnancy in Scarred Uterus

Summary: termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to misoprostol alone


Eligibility criteria:
inclusion criteria: * minimum age of 18 years for mother. * non-viable fetus (missed abortion or blighted ovum) in the 1st trimester of pregnancy evidenced by criteria for diagnosis by tvs . * previous c.s or myomectomy (1 or more ) * lack of any maternal diseases such as: heart disease, asthma, history of thromboembolism, cancer, renal failure, and liver diseases. exclusion criteria: * \* medical problem in patient * emergency conditions which need intervention . * history of allergy to misoprostol or letrozole drugs.
muscle training of patients with amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis

Summary: patients with neuropathic diseases are experiencing increasing muscle weakness, loss of muscle strength and functional abilities during their illness. in healthy people, regular exercise is the best way to maintain or improve muscle strength, endurance and general health status and thereby maintain functioning abilities. previously, patients with neuromuscular diseases were advised to avoid any kind of physical exercise. however, lately a number of studies have evaluated the effect of training in patients with neuromuscular diseases, and positive effects on the functional abilities have been found. based on these findings we want to investigate the mechanisms leading to development of muscle atrophy and loss of functional abilities, and to explore the opportunities of reducing muscle wasting and thereby improve the course of the disease development through strength training. the main objective is to investigate the effects of strength training on slowing disease progression and reduce the decline in muscle strength and function in patients with amyotrophic lateral sclerosis (als). in addition, the aim is to carry out detailed studies of biological processes in muscle tissue in order to unveil mechanisms leading to muscle atrophy, and to examine effects of a strength training program. the goal is to be able to incorporate strength training in the treatment program of these patients in order to maintain muscle strength and function in the individual for as long as possible. minimum 10 patients with the disease are included in the study. through a 12 week period the patients will participate in strength training 2-3 times per week. muscles biopsies will be taken (i) 12 weeks before commencement of strength training program, (ii) at the beginning of training and (iii) after 12 weeks of strength training. patients will function as their own controls. blood samples will be collected simultaneously in order to follow the development of the strength training. furthermore, participants will be assessed through at number of functional tests and questionnaires evaluating their strength, balance and social/ psychological status. subjects are recruited through their association with odense university hospital. in the present study, the participants become part of a social network, while participating in organized training sessions, and thus have a possibility to make contact with other als patients in the same situation as themselves.


Eligibility criteria:
inclusion criteria: * diagnosed with amyotrophic lateral sclerosis (als) exclusion criteria: * late stage als

Keywords: nervous system disease neurodegenerative disease motor neuron disease als muscle training muscle atrophy
genetic study of obstructive azoospermia

Conditions: Genetic Disease

Summary: in 1% of men with infertility, obstructive azoospermia (oa) may occur in congenital absence of the vas (cavd) or idiopathic obstructive azoospermia . many studies have shown that the pathogenic genes of oa are cftr and adgrg2 genes, and the inheritance mode is autosomal recessive. although the conventional assisted reproductive technology(pesa/tesa) can help these patients have children, male patients who carry mutations of the disease-causing genes (cftr and adgrg2) will also pass on their mutations to the next generation, which will increase the risk of male offspring infertility. therefore, genetic detection of cftr and adgrg2 genes is very necessary for cavd patients before assisted reproduction. genetic diagnosis plays a key role in preventing the disease to the offspring.


Eligibility criteria:
inclusion criteria: * no sperm was found after centrifugation for 15min for two or more semen tests, and the interval between two tests was at least 2 weeks. * blood fsh is normal; * hematostatin b is normal; * chromosome karyotype is normal or polymorphic; * y chromosome microdeletion did not show the deletion:(main locus); * biochemical fructose of seminal plasma : less than the normal value; * ph of semen \<7.2; * transscrotal or transrectal ultrasound: normal testicular size(as measured by b ultrasound), presence or dysplasia of vas deferens and epididymis; exclusion criteria: * b ultrasound of urinary system suggested abnormal development; * transscrotal or transrectal ultrasound indicated absence of vas deferens or epididymis or seminal vesicle; * physical examination showed the following abnormalities: cryptorchidism, tenderness of testis and epididymis; * the following medical history: genitourinary tract trauma or surgical history; orchitis; epididymitis; seminal vesicle disease; mumps; * laboratory examination: red and white blood cell elevation of semen routine

Keywords: cftr adgrg2 obstructive azoospermia
effectiveness of toric intraocular lenses for treating corneal astigmatism in patients with cataract and previous dalk

Conditions: Corneal Astigmatism in Cataract Patients and Previous DALK

Summary: the purpose of this study was to assess the efficacy of custom made toric intraocular lens implantation in patients with simultaneous post-dalk high corneal astigmatism and cataract.

patients undergoing cataract surgery after dalk for keratoconus were enrolled. total corneal astigmatism (tca)was assessed by a rotating scheimpflug camera combined with placido disk corneal topography (sirius; cso, firenze, italy). a customized toric iol (fil 611 t, soleko) was implanted in all eyes. one year postoperatively, refraction was measured, the iol position was recorded, and vectorial and non-vectorial analysis were performed to evaluate the correction of astigmatism.

Eligibility criteria:
inclusion criteria: * corneal suture removal had been performed in all cases at least 1 year before cataract surgery. corneal astigmatism was stable at least since 6 months before the cataract surgery exclusion criteria: * other ocular pathologies as glaucoma, retinal disease.
effects of a hip flexor and extensor muscle training program in individuals with chronic mechanical low back pain

Conditions: Chronic Low-back Pain (cLBP)

Summary: the goal of this clinical trial is to evaluate the effect of a physiotherapy intervention program in the lumbopelvic area in chronic low back pain patients. the main questions it aims to answer are: 1. is a specific stretching and strengthening program for the hip musculature beneficial for function and symptom reduction in patients with non-specific chronic low back ain? 2. are patients who have greater hip extension dysfunction going to benefit more from a specific program of stretching and strengthening of hip muscles? 3. are there more alteration in pelvis alignement and movement in standig position compared to seated position in those patiens with lesser hip range of movement? 4. are patiens with lesser hip range of movement going to show more dysfunction in the lumbopelvic region? participants will: * visit the physiotherapy clinic once a week to complete the therapeutic exercise session. * repeat the session in their houses if its possible between 3 or 4 times a week and record the number of days they repeat the session at home. * answer some questionaires at the begining of the intervention, after 4 weeks, a month and three months.

this study aims to enhance healthcare interventions for chronic low back pain, focusing specifically on patients whose pain may be linked to restricted hip extension mobility. patients will be referred from the healthcare system to the physiotherapy center, where the principal investigator, lucía vicente, will randomize participants into either the intervention or control group. each participant will complete an initial evaluation at the start of the intervention and again after 4 weeks. additional questionnaires will be administered one and three months post-intervention. pelvic movement changes will also be tracked before each in-person session. the program will focus on strengthening the pelvic muscles, particularly by targeting hip extensor strengthening and hip flexor stretching.

Eligibility criteria:
inclusion criteria: * age greater than 18 and less than 70 years. * low back pain lasting more than 3 months defined as: "pain or discomfort localized below the costal margin and above the gluteal fold, with or without referred pain to the leg." * low back pain with a mechanical component. * signed informed consent prior to participation in the study. exclusion criteria: * a specific cause for their low back pain (trauma, spondylolisthesis, vertebral fractures, etc.), have undergone any surgical procedures on the spine or hip, or have other diseases or conditions (neurological issues, joint replacements, etc.). * cognitive impairment and inability to comprehend. * injections in the last 6 months or physiotherapy treatment in the last 3 months.

Keywords: chronic low back pain hip flexors exercise therapy lumbopelvic function
effects of theraband resistance training on muscle strength in coronary artery diseases

Conditions: Coronary Artery Disease

Summary: to compare the effects of theraband resistance training with conventional resistance training on muscle strength in coronary artery diseases


Eligibility criteria:
inclusion criteria: * participants having a documented diagnosis of cad, confirmed by a medical professional. * individuals with a history of myocardial infarction (heart attack), angina, or evidence of significant coronary artery stenosis. * stable cad who were not experiencing acute coronary events, such as recent heart attacks or unstable angina. * patients who were able to perform exercises with theraband. * reduced muscle strength of upper limb/lower limb exclusion criteria: * patients over the age of 75 years. * exclude individuals with a recent history of theraband resistance training. * severe cardiovascular complications such as heart failure with reduced ejection fraction, severe arrhythmias, or uncontrolled hypertension. * patients with unstable conditions or cardiac episodes. * individuals who had undergone major cardiovascular surgery (e.g., coronary artery bypass grafting) within the last six months. * ejection fraction \< 40%
ele-101 safety & tolerability study in healthy participants and patients with depression

Conditions: Healthy Volunteers; Major Depressive Disorder; Depression

Summary: a study to assess the safety and tolerability of a drug called ele-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (part 1) and in patients with depression (part 2).

this is a 2-part study. part 1 is a phase i, double-blind, placebo-controlled, randomized study to assess the safety, tolerability, pharmacokinetic (pk) profile, pharmacodynamic (pd) and subjective drug intensity (sdi) of single ascending intravenous (iv) doses of ele-101 in healthy male and female adult participants. part 2 is a phase iia, open-label study to evaluate a range of pharmacodynamic effects of a single intravenous dose of ele-101 in patients with depression. healthy participants will receive either ele-101 or placebo as an iv infusion in part 1 and patients with mdd will receive ele-101 as an iv infusion in part 2.

Eligibility criteria:
inclusion criteria: * healthy male or female participants aged 18 to 65 years, inclusive. * participants have a body mass index (bmi) of 18 to 35 kg/m2, inclusive. * participants are able and willing to give written informed consent, adhere to the compliance terms during participation in the study, undergo the examinations and testing set forth in the study protocol and clearly and reliably communicate their subjective symptoms to the investigator. * part 2 only: patient has a diagnosis of mdd and is not on antidepressant medication. exclusion criteria: * current, or history (within the last 6 months) of, alcohol or substance use disorder. * use of pharmacological compounds for psychiatric or neurological conditions acting on the cns within 30 days or 5 half-lives (whichever is longer) prior to screening. * current or clinically relevant history of schizophrenia, psychotic, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder or panic disorder. * in first-degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder. * history of a diagnosis of hallucinogen persistent perceptual disorder (hppd). * significant suicide risk. * other personal circumstances and behavior that is incompatible with establishment of rapport or safe exposure to psilocin, as judged by the investigator. * part 1 only: ongoing current mdd, or history of mdd within the last year.

Keywords: ele-101 psilocin ele-psilo psilocybin psychedelic